Please wait while the formulary information is being retrieved.
Drug overview for RAYALDEE (calcifediol):
Generic name: CALCIFEDIOL (KAL-sif-e-DYE-ol)
Drug class: Vitamin D
Therapeutic class: Metabolic Modifiers
Calcifediol (25-hydroxycholecalciferol, 25-hydroxyvitamin D3) is a vitamin D analog.
No enhanced Uses information available for this drug.
Generic name: CALCIFEDIOL (KAL-sif-e-DYE-ol)
Drug class: Vitamin D
Therapeutic class: Metabolic Modifiers
Calcifediol (25-hydroxycholecalciferol, 25-hydroxyvitamin D3) is a vitamin D analog.
No enhanced Uses information available for this drug.
DRUG IMAGES
RAYALDEE ER 30 MCG CAP (SOFT)
The following indications for RAYALDEE (calcifediol) have been approved by the FDA:
Indications:
Hyperparathyroidism secondary to chronic renal failure
Professional Synonyms:
Hyperparathyroidism secondary to CRF
Indications:
Hyperparathyroidism secondary to chronic renal failure
Professional Synonyms:
Hyperparathyroidism secondary to CRF
The following dosing information is available for RAYALDEE (calcifediol):
Dosage of calcifediol, which is commercially available for oral use as the monohydrate, is calculated on the anhydrous basis.
The recommended initial dosage of calcifediol for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (i.e., serum total 25-hydroxyvitamin D concentration of less than 30 ng/mL) is 30 mcg once daily (as extended-release capsules). Serum calcium concentration should be less than 9.8 mg/dL prior to initiation of calcifediol therapy.
(See Hypercalcemia under Cautions: Warnings/Precautions.)
The maintenance dosage of calcifediol should be individualized to achieve a serum total 25-hydroxyvitamin D concentration within the range of 30-100 ng/mL, intact parathyroid hormone (iPTH) concentration within the desired therapeutic range, albumin-corrected serum calcium concentration within the normal range, and serum phosphorus concentration of less than 5.5 mg/dL. Serum calcium, phosphorus, total 25-hydroxyvitamin D, and iPTH concentrations should be monitored at a minimum of 3 months after initiation of therapy or dosage adjustment, and subsequently at least every 6-12 months during therapy.
The dosage of calcifediol should be increased to 60 mcg once daily (as extended-release capsules) after approximately 3 months if iPTH concentration remains above the desired therapeutic range, provided that the serum calcium concentration is less than 9.8 mg/dL, serum phosphorus concentration is less than 5.5 mg/dL, and serum total 25-hydroxyvitamin D concentration is less than 100 ng/mL.
Calcifediol therapy should be interrupted if iPTH concentration is persistently and abnormally low (to reduce the risk of adynamic bone disease), if serum calcium concentration consistently exceeds the upper limit of normal (ULN) (to reduce the risk of hypercalcemia), or if serum total 25-hydroxyvitamin D concentration consistently exceeds 100 ng/mL. Calcifediol should be resumed at a lower dosage after the abnormal values have returned to normal.
Nephrology experts currently state that the optimal iPTH concentration for patients with stage 3a (estimated glomerular filtration rate (eGFR) 45-59 mL/minute per 1.73 m2) to stage 5 (eGFR less than 15 mL/minute per 1.73 m2) CKD who are not undergoing dialysis is unknown, but modest increases in iPTH concentration may represent an appropriate adaptive response to declining renal function. For patients with stage 5 CKD undergoing dialysis, some experts suggest that iPTH concentrations may be maintained within a range of approximately 2-9 times the assay's ULN (which may correspond to a range of approximately 130-600 pg/mL for commercially available assays ).
Although some clinicians suggest that this range is too broad, available assays for PTH exhibit substantial variability; the previously recommended range of 150-300 pg/mL for patients with stage 5 CKD requiring dialysis was based on an assay that is no longer commercially available. Oversuppression of PTH may increase the risk of adynamic bone disease and should be avoided. (See Uses: Mineral and Bone Disorder Secondary to Chronic Renal Disease, in the Vitamin D Analogs General Statement 88:16.) Nephrology experts currently recommend that the individual values for serum calcium and phosphorus (evaluated together) be used instead of the mathematical construct of calcium times phosphorus product to guide clinical practice.
The recommended initial dosage of calcifediol for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (i.e., serum total 25-hydroxyvitamin D concentration of less than 30 ng/mL) is 30 mcg once daily (as extended-release capsules). Serum calcium concentration should be less than 9.8 mg/dL prior to initiation of calcifediol therapy.
(See Hypercalcemia under Cautions: Warnings/Precautions.)
The maintenance dosage of calcifediol should be individualized to achieve a serum total 25-hydroxyvitamin D concentration within the range of 30-100 ng/mL, intact parathyroid hormone (iPTH) concentration within the desired therapeutic range, albumin-corrected serum calcium concentration within the normal range, and serum phosphorus concentration of less than 5.5 mg/dL. Serum calcium, phosphorus, total 25-hydroxyvitamin D, and iPTH concentrations should be monitored at a minimum of 3 months after initiation of therapy or dosage adjustment, and subsequently at least every 6-12 months during therapy.
The dosage of calcifediol should be increased to 60 mcg once daily (as extended-release capsules) after approximately 3 months if iPTH concentration remains above the desired therapeutic range, provided that the serum calcium concentration is less than 9.8 mg/dL, serum phosphorus concentration is less than 5.5 mg/dL, and serum total 25-hydroxyvitamin D concentration is less than 100 ng/mL.
Calcifediol therapy should be interrupted if iPTH concentration is persistently and abnormally low (to reduce the risk of adynamic bone disease), if serum calcium concentration consistently exceeds the upper limit of normal (ULN) (to reduce the risk of hypercalcemia), or if serum total 25-hydroxyvitamin D concentration consistently exceeds 100 ng/mL. Calcifediol should be resumed at a lower dosage after the abnormal values have returned to normal.
Nephrology experts currently state that the optimal iPTH concentration for patients with stage 3a (estimated glomerular filtration rate (eGFR) 45-59 mL/minute per 1.73 m2) to stage 5 (eGFR less than 15 mL/minute per 1.73 m2) CKD who are not undergoing dialysis is unknown, but modest increases in iPTH concentration may represent an appropriate adaptive response to declining renal function. For patients with stage 5 CKD undergoing dialysis, some experts suggest that iPTH concentrations may be maintained within a range of approximately 2-9 times the assay's ULN (which may correspond to a range of approximately 130-600 pg/mL for commercially available assays ).
Although some clinicians suggest that this range is too broad, available assays for PTH exhibit substantial variability; the previously recommended range of 150-300 pg/mL for patients with stage 5 CKD requiring dialysis was based on an assay that is no longer commercially available. Oversuppression of PTH may increase the risk of adynamic bone disease and should be avoided. (See Uses: Mineral and Bone Disorder Secondary to Chronic Renal Disease, in the Vitamin D Analogs General Statement 88:16.) Nephrology experts currently recommend that the individual values for serum calcium and phosphorus (evaluated together) be used instead of the mathematical construct of calcium times phosphorus product to guide clinical practice.
Calcifediol extended-release capsules are administered orally at bedtime and should be swallowed whole. If a dose of calcifediol is missed, an extra dose should not be taken. Instead, the missed dose should be skipped and the next dose administered at the next regularly scheduled time.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| RAYALDEE ER 30 MCG CAP (SOFT) | Maintenance | Adults take 1 capsule (30 mcg) by oral route once daily at bedtime |
| RAYALDEE ER 30 MCG CAP (HARD) | Maintenance | Adults take 1 capsule (30 mcg) by oral route once daily at bedtime |
No generic dosing information available.
The following drug interaction information is available for RAYALDEE (calcifediol):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Burosumab/Oral Phosphates; Active Vitamin D Analogs SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Both burosumab and phosphates or vitamin D may increase serum phosphate levels. This combination may lead to greater increases in serum phosphate than anticipated. CLINICAL EFFECTS: The combination of burosumab with oral phosphates or active vitamin D analogs may result in hyperphosphatemia and may increase the risk of nephrocalcinosis.(1) PREDISPOSING FACTORS: Patients with renal impairment have alterations in mineral metabolism that may increase the risk of hyperphosphatemia.(1) PATIENT MANAGEMENT: The concomitant use of burosumab with oral phosphates or active vitamin D analogs is contraindicated. Discontinue oral phosphate and/or active vitamin D analogs one week before starting burosumab.(1) DISCUSSION: Burosumab restores dysfunctional renal phosphate reabsorption and renal production of 1,25-dihydroxyvitamin D to treat X-linked hypophosphatemia. Additional oral phosphates and/or active vitamin D analogs may raise serum phosphate higher than anticipated. |
CRYSVITA |
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Erdafitinib/Serum Phosphate Level-Altering Drugs SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Medications that alter serum phosphate may interfere with interpretation of phosphate levels that are needed to determine initial erdafitinib dose.(1) CLINICAL EFFECTS: Serum phosphate levels that are elevated by concomitant medications may result in an inappropriately low dose and decreased effectiveness of erdafitinib. Serum phosphate levels that are decreased by concomitant medications may result in an inappropriately high dose and increased toxicity from erdafitinib. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of erdafitinib states that agents that alter serum phosphate levels should be avoided before the initial dose increase period for erdafitinib based on serum phosphate levels (days 14 to 21).(1) DISCUSSION: Concomitant administration of serum phosphate level-altering agents during the initial dose increase period of erdafitinib based on serum phosphate levels (days 14 to 21) may interfere with serum phospate levels and lead to incorrect dosing of erdafitinib.(1) Agents that may alter serum phosphate levels linked to this monograph include: aluminum carbonate, aluminum hydroxide, calcium acetate, calcium carbonate, calcium citrate, cod liver oil, ferric citrate, lanthanum, magnesium carbonate, magnesium hydroxide, potassium phosphate, sevelamer, sodium phosphate, sucroferric oxyhydroxide, tenapanor, and vitamin D.(1) |
BALVERSA |
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Orlistat/Fat Soluble Vitamins SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The acetate ester forms of vitamin A and vitamin E must undergo hydrolysis for absorption from the gastrointestinal tract.(1) The enzyme responsible for this hydrolysis is inhibited by orlistat.(2) CLINICAL EFFECTS: Orlistat may reduce absorption of fat soluble vitamins, leading to a deficiency state. PREDISPOSING FACTORS: A pre-existing deficiency of fat soluble vitamins (A,D,E and K) or chronic malabsorption syndrome. PATIENT MANAGEMENT: The inhibition of fat soluble vitamin absorption by orlistat should be borne in mind during implementation of a vitamin supplementation strategy. Patients should be strongly encouraged to take a multivitamin supplement which contains fat soluble vitamins, particularly Vitamin D as it appears most susceptible to this interaction.(4,5) Multivitamin supplements should be taken at least two hours before or after the dose of orlistat, or at bedtime.(4) Patients with chronic malabsorption syndromes should not receive orlistat.(4) DISCUSSION: Adult patients taking orlistat without supplementation showed a greater reduction in vitamin A,D,E and beta-carotene levels compared to placebo during two or more consecutive visits in studies of 1-2 years duration; these patients had normal baseline values prior to orlistat therapy. Low vitamin values in orlistat patients were as follows: low Vitamin D 12%, low beta-carotene 6.1%, low Vitamin E 5.8%, low Vitamin A 2.2%.(4) A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption and a 60% decreased in vitamin E acetate absorption with concomitant orlistat.(4) In a study, orlistat produced the vitamin net concentration by approximately 43%.(1) In a study, no statistically significant decrease in vitamin A absorption was observed with concurrent orlistat.(2) In a study, mean vitamin D levels were significantly reduced compared with baseline after one month of orlistat therapy despite multivitamin supplementation.(5) |
ORLISTAT, XENICAL |
| Colesevelam/Fat Soluble Vitamins SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Colesevelam may decrease the absorption of fat-soluble vitamins A, D, E, and K.(1) CLINICAL EFFECTS: Colesevelam may reduce absorption of fat soluble vitamins, leading to a deficiency state. PREDISPOSING FACTORS: A pre-existing deficiency of fat soluble vitamins (A,D,E and K) or chronic malabsorption syndrome. PATIENT MANAGEMENT: The inhibition of fat soluble vitamin absorption by colesevelam should be borne in mind during implementation of a vitamin supplementation strategy. Oral multivitamin supplements should be taken at least four hours before the dose of colesevelam.(1) DISCUSSION: Colesevelam may decrease the absorption of fat-soluble vitamins A, D, E, and K.(1) |
COLESEVELAM HCL, WELCHOL |
The following contraindication information is available for RAYALDEE (calcifediol):
Drug contraindication overview.
The manufacturer states that there are no known contraindications to the use of calcifediol.
The manufacturer states that there are no known contraindications to the use of calcifediol.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Hypervitaminosis D |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Hypercalcemia |
| Hyperphosphatemia |
| Kidney stone |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Sarcoidosis |
The following adverse reaction information is available for RAYALDEE (calcifediol):
Adverse reaction overview.
Adverse effects reported during clinical trials in 1.4% or more of patients receiving calcifediol extended-release capsules and more frequently than in those receiving placebo include anemia, nasopharyngitis, increased serum creatinine concentrations, dyspnea, cough, congestive heart failure, constipation, bronchitis, hyperkalemia, osteoarthritis, hyperuricemia, contusion, pneumonia, and chronic obstructive pulmonary disease.
Adverse effects reported during clinical trials in 1.4% or more of patients receiving calcifediol extended-release capsules and more frequently than in those receiving placebo include anemia, nasopharyngitis, increased serum creatinine concentrations, dyspnea, cough, congestive heart failure, constipation, bronchitis, hyperkalemia, osteoarthritis, hyperuricemia, contusion, pneumonia, and chronic obstructive pulmonary disease.
There are 7 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Anemia Chronic heart failure |
Chronic obstructive pulmonary disease Hyperkalemia Pneumonia |
| Rare/Very Rare |
|---|
|
Adynamic bone disease Hypercalcemia |
There are 6 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Constipation Dyspnea Pharyngitis |
Arthritis Bruising Hyperuricemia |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for RAYALDEE (calcifediol):
Safety and efficacy of calcifediol extended-release capsules have not been established in pediatric patients.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. (See Users Guide.) Calcifediol has been shown to be teratogenic in rabbits when given at dosages of 8-16 times the recommended human dosage of 60 mcg daily (based on body surface area) but was not teratogenic in rats at dosages up to 60 mcg/kg daily. There are no adequate and well-controlled studies to date using calcifediol in pregnant women. Calcifediol should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
Limited data indicate that calcifediol is minimally distributed into milk in humans. Calcifediol should be used with caution in nursing women.
Of the total number of patients studied in phase 3, placebo-controlled, clinical trials of calcifediol extended-release capsules, 63% were 65 years of age and older, while 22% were 75 years of age and older. No overall differences in safety or efficacy were observed between geriatric patients and younger adults.
The following prioritized warning is available for RAYALDEE (calcifediol):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for RAYALDEE (calcifediol)'s list of indications:
| Hyperparathyroidism secondary to chronic renal failure | |
| N25.81 | Secondary hyperparathyroidism of renal origin |
Formulary Reference Tool